Purpose: To comprehensively review the available published literature for cross-linking in the pediatric population.
K eratoconus is a noninflammatory progressive corneal thinning disorder resulting in biomechanical weakening. 1, 2 It manifests as corneal thinning and protrusion resulting in moderate to severe visual impairment from irregular astigmatism. It commonly commences at puberty 3 ; however, most cases of keratoconus are diagnosed later, on average at age 27 years. 1, 4 Diagnosis of keratoconus in the pediatric population has been reported as early as age 4, 5 with rapid and severe progression. Until recently, penetrating keratoplasty (PK) was the only treatment alternative for visual rehabilitation in severe cases of keratoconus where contact lens fitting was not possible. Corneal cross-linking (CXL) has been offered as treatment of keratoconus in many countries since its initial description in 2003 and was approved by the US Food and Drug Administration (FDA) in 2016 for treatment of progressive keratoconus in patients older than 14 years. Long-term follow-up studies have demonstrated a halt in progression and reduction in corneal steepness in most treated patients. A review of the literature on the use of CXL in the pediatric population is presented and is primarily focused on unique aspects of diagnosis, current management strategies, and gaps in the understanding of disease presentation and management as compared to the adult population.
METHODS
A review of the literature published in English was conducted in PubMed using the following search terms: "Cross-linking" AND "pediatric" (187 results); "Cross-linking" AND "children" (210 results); and "Cross-linking" AND "adolescents" (12 results). One hundred fifteen publications were found to be salient to this review.
KERATOCONUS: EPIDEMIOLOGY
Keratoconus prevalence has been reported as 54.5 per 100,000 affected patients in the United States, 6 0.3 per 100,000 in Russia, 7 2300 per 100,000 in Central India, 8 6200 per 100,000 in Saudi Arabia, 9 and 13.3 per 100,000 in the Netherlands. 10 This variability may be explained by changes in the available imaging technology over time because as newer publications emerge, the reported incidence of keratoconus has increased.
Keratoconus has been associated with atopy, 11,12 vernal keratoconjunctivitis, [13] [14] [15] and environmental factors such as persistent eye rubbing and eyelid laxity. 16, 17 There is a higher prevalence of keratoconus in patients with Down syndrome 18 ; however, the genetic correlation has not been conclusive, and the presence of keratoconus in these patients is also likely associated with persistent eye rubbing. Other genetic conditions such as Leber congenital amaurosis 19 and mitral valve prolapse 1, 20, 21 have been genetically linked to keratoconus, and numerous publications have shown strong genetic predisposition, [22] [23] [24] with identified potential linked genes. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] When subclinical forms of keratoconus and forme fruste keratoconus are taken into account, first-degree relatives of patients with keratoconus have 15 to 67 times higher prevalence of keratoconus compared with the general population. 41 
KERATOCONUS IN THE PEDIATRIC POPULATION
In the pediatric population, prevalence data have not been widely reported in the literature. The largest population study of 2972 patients younger than 14 years in Lebanon reported an incidence of 0.53% (approximately 1 in 200) over a period of 5 years, which represented 2.9% of keratoconus cases in all ages, 42 and more recently, a prevalence of 1 in 25 was reported in Riyadh, Saudi Arabia. 43 The average age at diagnosis in the pediatric population is 15 years, 44, 45 with reported cases diagnosed as early as age 4 5 and male predominance. [46] [47] [48] Keratoconus tends to be more severe and to progress more rapidly in children, [49] [50] [51] especially those with central cones, which are more common in this population and more visually significant than peripheral cones. 45 At the time of presentation, 30% of children and adolescents present with keratoconus at stage 4 (Table 1) 52,53 compared with 8% of adults, 50 and in up to 88% of pediatric patients, progression can occur rapidly with steepening greater than 2 D within 12 months after presentation. [54] [55] [56] In addition, patients with asymmetric disease have been shown to eventually develop keratoconus in their unaffected eye in 35% of cases with unpredictable timing over the course of 8 years. These findings were confirmed in the Collaborative Longitudinal Evaluation of Keratoconus study, identifying age between 10 and 20 years as a predictor of significant progression and corneal scaring. 57 Reports in the literature about pediatric keratoconus are limited, and there is still no standardization for management in pediatric patients. Paradigms in management of keratoconus in adults are shifting, with introduction of new treatments such as corneal CXL and incorporation of intracorneal ring segments into the management of ectatic disease. These therapeutic options are also being assessed in the pediatric population, with increasing publications describing treatment outcomes.
CORNEAL CXL FOR PEDIATRIC KERATOCONUS
Penetrating keratoplasty (PK) has a poorer prognosis in the pediatric population because of an increased risk of rejection related to its robust inflammatory response to the graft. 58 Over the past decade, CXL has emerged as a less invasive alternative for patients with progressive keratoconus, offering significant improvement in the procedure risk profile compared with PKP. The use of keratoplasty for treatment of severe keratoconus has steadily decreased in the United States 59 and will decline further with FDA approval of CXL.
Initially reported by Wollensak et al, 60 CXL improves corneal tensile strength through combination of riboflavin drops and exposure to ultraviolet A light. CXL has been thoroughly studied in the adult population and offers a minimally invasive alternative to halt progression, and in some cases, it regresses the severity of the ectatic process.
CXL PROTOCOLS
The first protocol proposed for CXL was the standard (Dresden) protocol by Wollensak et al, 60, 61 and it is currently the only FDA-approved protocol in the United States. 62 Other proposed protocols include accelerated protocols that reduce the treatment time but maintain or increase total irradiance 63, 64 and transepithelial CXL, which attempts to bypass the epithelial barrier by modifying riboflavin to increase its penetration through an intact epithelium. 65 
Standard Dresden Protocol
Because the corneal epithelium poses a barrier to full penetration of standard riboflavin into the corneal stroma, 66 the standard protocol requires mechanical debridement of the corneal epithelium under topical anesthesia in the central 9 mm of the cornea. One drop of riboflavin 0.1% solution is then administered every 2 minutes for 30 minutes, followed by exposure to ultraviolet-A light (370 6 5 nm wavelength, 5.4 J/cm 2 irradiance) with instillation of the riboflavin solution every 2 minutes for an additional period of 30 minutes.
Accelerated CXL Protocols
Accelerated protocols have been derived from the Bunsen-Roscoe Law of Reciprocity of Photochemistry, which states that the photochemical effect of ultraviolet light is proportional to the total amount of energy delivered and should be equivalent for equivalent total doses regardless of the relative irradiation time and intensity for each protocol. 63 Results to date are controversial. Animal studies found equivalent efficacy between 3 mW at 30 minutes and 9 mW at 10 minutes, 67 and equivalent biomechanical responses are seen in patients treated with standard (3 mW/cm 2 , 30 minutes) and moderately accelerated (10 mW/cm 2 , 9 minutes) treatment protocols. 64, 68 However, there seems to be a drop in efficacy when higher irradiances are used, 69 to a point indistinguishable from untreated control corneas, 70 because of the imbalance between conversion and replenishment of oxygen molecules. 70, 71 In the pediatric population, very few studies have evaluated outcomes of accelerated protocols with ultraviolet fluence of 30 mW/cm 2 for 3 minutes, 10 mW/cm 2 for 9 minutes, and 9 mW/cm 2 for 10 minutes. [72] [73] [74] Results have been promising in terms of refractive outcomes and keratometry improvement; however, to date, no studies have compared the efficacy of accelerated protocols with the standard protocol in children, and no studies have followed patients beyond 3 years, when the effects of the standard protocol may start regressing in children. 55 Transepithelial CXL
Transepithelial CXL emerged as a strategy to improve the safety profile and reduce postoperative discomfort. However, studies on porcine corneas 75 and in vitro human corneas have demonstrated reduced penetration of riboflavin into the corneal stroma when the epithelium remains intact. 66 As a response to this, modified riboflavin was developed, Ricrolin TE (Sooft Italia SpA, Italy), with addition of 2 agents, trometamol and sodium ethylenediaminetetraacetic acid that enhance penetration through the intact epithelium was then introduced to the transepithelial CXL protocol to maximize the effect of the procedure. Even with this modification, there is less penetration into the corneal stroma and limited clinical results. [76] [77] [78] [79] The demarcation line, a refractile line seen within the corneal stroma on ocular coherence tomography by days 10 to 14 after CXL, is believed to represent penetration of treatment into the stroma. 80 In transepithelial CXL, this demarcation line is seen at an average depth of 100 mm below the epithelium 81 compared with 320 to 340 mm after epithelium-off treatments, indicating that the epithelium does pose a barrier to penetration of CXL treatments into the corneal stroma.
Iontophoresis
Because riboflavin is a low-molecular-weight and negatively charged molecule, another proposed strategy for transepithelial CXL treatments is the use of iontophoresis, applying a small electric current before instillation of riboflavin to enhance its penetration into the corneal stromal tissue. Early studies in rabbit models have shown promising results in terms of penetration into the corneal stroma compared with epithelium-off CXL, 82, 83 and in vitro studies have shown similar biomechanical changes in the cornea compared with the standard CXL protocol. 84 However, the demarcation line in adults is only present in 47% of patients 1 month after treatment compared with 93% and 87% after conventional and accelerated CXL protocols, respectively, 85 and to date, there are limited publications in the literature demonstrating stable refractive and keratometric values in pediatric patients 15 to 18 months after treatment. 86, 87 
OUTCOMES OF PEDIATRIC CXL
The standard CXL protocol has been shown to successfully halt progression of keratoconus and reduce keratometry values in adults. 88, 89 Since the first publication in a pediatric population in 2011, 56 numerous publications have shown that standard epithelium-off Dresden protocol CXL is as safe and effective for the treatment of progressive keratoconus in children and adolescents as it is in the adult population (Table 2) . 45, 48, 55, [90] [91] [92] [93] [94] The number of publications assessing the results from transepithelial and accelerated protocols in pediatric patients also continues to increase (Tables 3 and 4) .
There are no randomized, contralateral eye studies comparing treatment at diagnosis to treatment on detection of progression; however, because of the rapid and severe progression of keratoconus in children and adolescents, most authors suggest proceeding with treatment at the time of diagnosis. 55 
Efficacy
After the standard CXL epithelium-off protocol, most pediatric patients experience flattening of the steepest keratometry up to 10 years after the procedure. 55, [72] [73] [74] 90, 92, [95] [96] [97] [98] By contrast, published studies assessing the effect of transepithelial CXL provide conflicting evidence (Table 3) , with some showing comparable 99, 100 or less pronounced effect 101 and even topographic regression 9 to 12 months after epithelium-on procedures. 78, 102 The advantage of transepithelial CXL is to offer minimally invasive treatment with a potentially better safety profile because of the intact epithelium. However, given its diminished effect, transepithelial CXL may be reserved for use in patients who present with early disease stages or in specific patient populations, such as patients with Down syndrome and other special considerations, who may pose challenges with postoperative compliance.
Topographic Effects
The response to CXL in pediatric patients seems to occur more robustly in patients with thinner corneas (,450 mm) 48, 97 and centrally located cones. 45 Initial steepening of the cornea during the first 3 months after the procedure has been observed, 94, 96 which has been suggested to be the result of early epithelial remodeling. 103 Beyond the first year and during the first 2 years after the standard CXL epithelium-off protocol, 25% of patients remain stable, and more than 60% show regression, which is manifested as average flattening of 1.5 D in the steepest keratometry, whereas 11% to 20% show no response to treatment with progression of corneal steepening. 55, [72] [73] [74] 90, 92, [95] [96] [97] After 2 years, a halt in the flattening effect has been observed, and 3 years after the procedure 20% to 50% of patients may resume progression of corneal steepening despite initial improvement, 55, 96, 98 indicating a transient effect of CXL in this population that may not be sufficient to completely and permanently halt progression. Some factors identified as influencing progression of keratoconus long term after CXL are paracentral location of the cone 47 (odds ratio 3.21, 95% confidence interval) and thinnest pachymetry below 450 mm (odds ratio of 4.54, 95% confidence interval). 104 There are very few retreatment cases published in the literature. In an adult patient, retreatment resulted in further 4 D of flattening in Kmax over a period of 2 years. 105 In a recently published series of 62 eyes of pediatric patients, 2 children showed progression up to 3.2 D in Kmax by the 36-month follow-up visit, requiring retreatment. Both patients experienced stabilization of Kmax values 12 months after retreatment. 98 Transepithelial CXL also has been demonstrated to halt progression in up to 80% of patients, 86, 87, 99, 100 and in some reports, it has also been shown to improve keratometry values in a degree comparable with the standard Dresden protocol. 99, 100 However, improvement of keratometry values is not seen with transepithelial treatment as consistently as with the standard Dresden protocol, 86, 87, 102 and topographic regression has been documented 9 to 12 months after the procedure. 78, 102 Studies on accelerated protocols are sparse and with small groups of patients. However, results are promising in terms of improvement in keratometry measurements, especially in those protocols that use longer periods of exposure (9 and 10 minutes) 73 ,74 compared with much shorter exposures. 72 
Refractive Effects
Although the most relevant effect of CXL is the halt in progression of the disease, refractive improvement can be seen in different stages of keratoconus after all CXL protocols. Uncorrected distance visual acuity and corrected distance visual acuity can improve an average of 1 to 2 and 2 to 3 lines, respectively, in 30% to 60% of patients by year 2, 45, 55, 92, 93, 106 and 69% by year 4 96 after the standard Dresden protocol. There can also be significant reduction in higher-order aberrations, specifically total coma and spherical aberration. 48, 55, 72, 90, 94 Changes in visual acuity after transepithelial CXL are less clinically significant, 99, 102 occasionally with no change 86, 87, 100 ; In accelerated CXL protocols, refractive changes are also less, but more apparent after longer exposures (9-10 minutes). [72] [73] [74] Safety Although microbial keratitis after CXL is infrequent, it has been reported after both standard and accelerated protocols in the pediatric population (Table 5) . [107] [108] [109] [110] Although most cases have occurred after epithelium off, microbial keratitis has also been reported after transepithelial and accelerated CXL treatments. 108, 111 The largest reported series of microbial keratitis after CXL was recently published by Maharana et al describing 7 cases of microbial keratitis in 532 CXL procedures using the accelerated 18 mW/cm 2 for 6 minutes. 112 All reported cases have occurred between day 1 and day 7 after CXL and having received prophylactic treatment with topical fluoroquinolones. Most microbiological reports have shown Staphylococcus aureus, but there have also been reports of Aspergillus fumigatus, Mucor spp, Acanthamoeba and Alternaria spp, 112 as well as Pseudomonas aeruginosa, 109 and herpes simplex. 107 No other major complications have been reported after different CXL protocols, except transient haze that usually resolves after treatment with topical steroids, 91, 98 although it can persist in 3% of patients. 47 There is a transient decrease in thinnest pachymetry during the first 6 months after the procedure, which returns to baseline after 1 year. 90, 92, 94 Endothelial cell counts have been shown to remain unaffected up to a 6-year follow-up period both after standard accelerated epithelium-off 94,100 protocols 72,74 and transepithelial protocols. 99 
Cost-Effectiveness
Cost-effectiveness analyses of CXL compared with traditional management of keratoconus using the Markov model structure 113, 114 and 2-state transitioning microsimulation models 115 have demonstrated superiority of early CXL over standard management with PKP. In a hypothetical model, a 10-year effect after early treatment with CXL would provide a net increase in quality-adjusted life years (QALY) of 50 to 51 with early CXL 113, 115 and incremental cost-effectiveness ratios of £3174/QALY, 114 €54,384 ($59,822)/QALY, 113 and Can $9090/QALY 115 compared with standard management.
CONCLUSION
The field of pediatric CXL is yet to be fully addressed, and the currently published literature on CXL is not as extensive for the pediatric population as it is for the adult population. Because clinical findings of keratoconus usually become evident during puberty 3 but can also present earlier in childhood, topographic screening should be considered in adolescents or children with high degrees of myopia and/ or astigmatism or anisometropia, especially when their distance-corrected visual acuity is not 20/20. In addition, because there seems to be a genetic predisposition, [22] [23] [24] topographic screening should also be considered in any child with a family history of keratoconus and in relatives of diagnosed children. Because of the evidence of rapid progression in most pediatric patients, 55 and the clear cost-effectiveness of early CXL compared with standard traditional management of KCN with late PKP, [113] [114] [115] Currently available evidence suggests that the standard CXL Dresden protocol is at least temporarily effective in halting progression and even improving keratometry values in pediatric patients. There has been a demonstrated regression up to 3 years after treatment in some studies, and to our knowledge, no studies have been published assessing the outcomes of retreatments in this population after resuming progression of keratoconus. Given the concern of regression of keratoconus after CXL in children, studies assessing the effect of CXL in pediatric patients should provide at least 5 years of follow-up data to fully determine long-term effects, and follow-up after CXL in pediatric patients should monitor for early signs of resumed progression. A better consensus should be established in terms of the age group included in the term "pediatric" to homogenize and compare results, and further studies are warranted to assess the long-term effect of CXL, the feasibility and effectiveness of retreatments, and to confirm the effectiveness of alternative protocols in selected cases.
